Pick the right molecule.

Every figure on this page is sourced from the citation index. Toggle compounds in or out to see the comparison you actually care about. Defaults: the four most common GLP-1-family questions we get from patients.

— Compare

— Quick visualisations

The numbers, charted.

Reported weight loss at peak dose

— % body weight, 48–72 wk · phase 2/3 RCTs

Plasma half-life

— hours, supports dosing frequency

HbA1c reduction (T2D cohorts)

— %-points, baseline 7.5–8.5

GI side-effect frequency

— % reporting nausea or GI disturbance

— Patient scenarios

"Which one for…"

— Scenario 01

Maximum weight loss research

Triple-agonism wins on raw weight outcomes.

— PickSemaglutide

— Scenario 02

Best evidence base

The conservative pick when weight loss isn't the top priority.

— PickSemaglutide

— Scenario 03

Best tolerability profile

Tirzepatide adds GIP agonism to GLP-1, which clinically appears to dampen GI side effects relative to semaglutide at matched weight-loss levels. The pragmatic pick for sensitive patients.

— PickTirzepatide

— Next

Need a deeper look?

The citation index lists every paper feeding this comparison. The safety matrix gives you the side-effect profile for each.

Safety matrix Take the matching quiz